CLEC3B Expression in Saliva and Serum: A Promising Biomarker Approach for Oral Squamous Cell Carcinoma: CLEC3B Expression in Saliva and Serum: Oral Squamous Cell Carcinoma

Syeda Zehra Ahmed; Shumaila Usman; Fouzia Shaikh; Atif Iqbal Butt; Uzma Zareef; Aliya Irshad Sani

doi:10.54393/pjhs.v6i8.3241

Authors

Syeda Zehra Ahmed Department of Pathology, Ziauddin Medical University, Karachi, Pakistan
Shumaila Usman Department of Molecular Medicine, Ziauddin Medical University, Karachi, Pakistan
Fouzia Shaikh Department of Pathology, Ziauddin Medical University, Karachi, Pakistan
Atif Iqbal Butt Department of Oral and Maxillofacial Surgery, Ziauddin Medical University, Karachi, Pakistan
Uzma Zareef Department of Oral Pathology, Liaquat College of Medicine and Dentistry, Karachi, Pakistan
Aliya Irshad Sani Department of Biochemistry, Ziauddin Medical University, Karachi, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v6i8.3241

Keywords:

Squamous Cell Carcinoma of Head and Neck, Gene Expression, Biomarkers, Saliva, Blood

Abstract

Metastasis, considered the most important factor for determining the survival rate of oral squamous cell carcinoma (OSCC). Therefore, a useful biomarker is needed to classify patients with OSCC in order to ensure effective treatment. Although CLEC3B has been mentioned in the literature, its relationship to OSCC has not yet been studied. Objectives: To evaluate the potential of CLEC3B expression in saliva and blood as a diagnostic biomarker for oral squamous cell carcinoma. Methods: A case-control study comprised of 80 samples (40 blood and 40 saliva) from 40 participants was conducted. Both Ziauddin University Hospital and Abbasi Shaheed Hospital served as the recruitment sites for all samples. RT qPCR was used to determine the expression levels of CLEC3B in OSCC and healthy individuals after obtaining written informed consent. Ziauddin University Ethical Review Committee approved this project. SPSS version 20.0 was used to analyze the data. Results: When compared to healthy people, OSCC patients' saliva had considerably lower levels of CLEC3B (p-value 0.001). Moreover, the expression was comparatively lower in the saliva of OSCC patients as compared to blood, suggesting that this marker can be better evaluated in saliva. Conclusions: Low expression of CLEC3B with the progression of OSCC depicts its tumor suppressive role in the tumor microenvironment. Its high yield in saliva can make it a suitable and easily assessable biomarker for determining OSCC progression.

References

Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2019. CA: A Cancer Journal for Clinicians. 2019 Jan; 69(1): 7-34. doi: 10.3322/caac.21551. DOI: https://doi.org/10.3322/caac.21551

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M et al. Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research On Cancer. 2020 Nov; 20182020.

Harwansh RK and Deshmukh R. Breast Cancer: An Insight into Its Inflammatory, Molecular, Pathological and Targeted Facets with Update on Investigational Drugs. Critical Reviews in Oncology/Hematology. 2020 Oct 1; 154: 103070. doi: 10.1016/j.critrevonc.2020.103070. DOI: https://doi.org/10.1016/j.critrevonc.2020.103070

Karim AA, Inam S, Zaidi AB. Inadequate Checks On Smokeless Tobacco Usage in Pakistan: Cultural Heritage or Policy Neglect. Journal of the Pakistan Medical Association. 2020 Sep; 70(1): 134-8. doi: 10.5455/JPMA.6459. DOI: https://doi.org/10.5455/JPMA.6459

Bschorer M, Schneider D, Goppold K, Sperling J, Schön G, Bschorer R. Quality of Life and Survival Rate After Primary Surgical Treatment of Oral Squamous Cell Carcinoma: A Retrospective Study with 18 Years of Follow-Up. Journal of Cranio-Maxillofacial Surgery. 2022 Feb; 50(2): 170-7. doi: 10.1016/j.jcms.2021.09.016. DOI: https://doi.org/10.1016/j.jcms.2021.09.016

Tan Y, Wang Z, Xu M, Li B, Huang Z, Qin S et al. Oral Squamous Cell Carcinomas: State of the Field and Emerging Directions. International Journal of Oral Science. 2023 Sep; 15(1): 44. doi: 10.1038/s41368-023-00249-w. DOI: https://doi.org/10.1038/s41368-023-00249-w

Shan J, Sun Z, Yang J, Xu J, Shi W, Wu Y et al. Discovery and Preclinical Validation of Proteomic Biomarkers in Saliva for Early Detection of Oral Squamous Cell Carcinomas. Oral Diseases. 2019 Jan; 25(1): 97-107. doi: 10.1111/odi.12971. DOI: https://doi.org/10.1111/odi.12971

Xie XW, Jiang SS, Li X. CLEC3B as a Potential Prognostic Biomarker in Hepatocellular Carcinoma. Frontiers in Molecular Biosciences. 2021 Jan; 7: 614034. doi: 10.3389/fmolb.2020.614034. DOI: https://doi.org/10.3389/fmolb.2020.614034

Dai W, Wang Y, Yang T, Wang J, Wu W, Gu J. Downregulation of Exosomal CLEC3B in Hepatocellular Carcinoma Promotes Metastasis and Angiogenesis Via AMPK and VEGF Signals. Cell Communication and Signaling. 2019 Sep; 17(1): 113. doi: 10.1186/s12964-019-0423-6. DOI: https://doi.org/10.1186/s12964-019-0423-6

Umapathy VR, Natarajan PM, Swamikannu B. Review Insights on Salivary Proteomics Biomarkers in Oral Cancer Detection and Diagnosis. Molecules. 2023 Jul; 28(13): 5283. doi: 10.3390/molecules28135283. DOI: https://doi.org/10.3390/molecules28135283

Jayasinghe RD, Hettiarachchi PV, Amugoda D, Kumaraarachchi M, Liyanage RL, Siriwardena BS et al. Validity of Toluidine Blue Test as A Diagnostic Tool for High Risk Oral Potentially Malignant Disorders-A Multicentre Study in Sri Lanka. Journal of Oral Biology and Craniofacial Research. 2020 Oct; 10(4): 547-51. doi: 10.1016/j.jobcr.2020.08.002. DOI: https://doi.org/10.1016/j.jobcr.2020.08.002

Delrue C, De Bruyne S, Speeckaert MM. Unlocking the Diagnostic Potential of Saliva: A Comprehensive Review of Infrared Spectroscopy and Its Applications in Salivary Analysis. Journal of Personalized Medicine. 2023 May; 13(6): 907. doi: 10.3390/jpm13060907. DOI: https://doi.org/10.3390/jpm13060907

Bel'skaya LV and Sarf EA. Biochemical Composition and Characteristics of Salivary FTIR Spectra: Correlation Analysis. Journal of Molecular Liquids. 2021 Nov; 341: 117380. doi: 10.1016/j.molliq.2021.117380. DOI: https://doi.org/10.1016/j.molliq.2021.117380

Roi A, Rusu LC, Roi CI, Luca RE, Boia S, Munteanu RI. A New Approach for the Diagnosis of Systemic and Oral Diseases Based on Salivary Biomolecules. Disease Markers. 2019; 2019(1): 8761860. doi: 10.1155/2019/8761860. DOI: https://doi.org/10.1155/2019/8761860

Song M, Bai H, Zhang P, Zhou X, Ying B. Promising Applications of Human-Derived Saliva Biomarker Testing in Clinical Diagnostics. International Journal of Oral Science. 2023 Jan; 15(1): 2. doi: 10.1038/s41368-022-00209-w. DOI: https://doi.org/10.1038/s41368-022-00209-w

Arellano-Garcia ME, Li R, Liu X, Xie Y, Yan X, Loo JA et al. Identification of Tetranectin as A Potential Biomarker for Metastatic Oral Cancer. International Journal of Molecular Sciences. 2010 Sep; 11(9): 3106-21. doi: 10.3390/ijms11093106. DOI: https://doi.org/10.3390/ijms11093106

Sajan T, Murthy S, Krishnankutty R, Mitra J. A Rapid, Early Detection of Oral Squamous Cell Carcinoma: Real Time PCR Based Detection of Tetranectin. Molecular Biology Research Communications. 2019 Mar; 8(1): 33.

Khidhir KG. Expression Profile of PBRM1, PLAU and CLEC3B Genes in Head and Neck Squamous Cell Carcinoma. Passer Journal of Basic and Applied Sciences. 2023 Jun; 5(1): 128-33.

Chen H, Liao K, Li L, Zhou Y, Wu S. CLEC3B Inhibits Proliferation and Radioresistance and Induces Apoptosis in BT549 Breast Cancer Cells. Journal of Radiation Research and Applied Sciences. 2024 Jun; 17(2): 100895. doi: 10.1016/j.jrras.2024.100895. DOI: https://doi.org/10.1016/j.jrras.2024.100895

Zhu HF, Zhang XH, Gu CS, Zhong Y, Long T, Ma YD et al. Cancer-Associated Fibroblasts Promote Colorectal Cancer Progression by Secreting CLEC3B. Cancer Biology and Therapy. 2019 Jul; 20(7): 967-78. doi: 10.1080/15384047.2019.1591122. DOI: https://doi.org/10.1080/15384047.2019.1591122

Sun J, Xie T, Jamal M, Tu Z, Li X, Wu Y et al. CLEC3B as a Potential Diagnostic and Prognostic Biomarker in Lung Cancer and Association with the Immune Microenvironment. Cancer Cell International. 2020 Apr; 20(1): 106. doi: 10.1186/s12935-020-01183-1. DOI: https://doi.org/10.1186/s12935-020-01183-1

Madunić J. The Urokinase Plasminogen Activator System in Human Cancers: An Overview of Its Prognostic and Predictive Role. Thrombosis and Hemostasis. 2018 Dec; 118(12): 2020-36. doi: 10.1055/s-0038-1675399. DOI: https://doi.org/10.1055/s-0038-1675399